Figure 2 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
Résumé fourni par la source
Association of NOUS-209 FSMs with cancer chronology, stage, and invasion. A, Mosaic plot showing the distribution of colorectal cancer and urothelial cancer across three cancer groups: first cancer (1st), second cancer (2nd), and third cancer or subsequent cancers (3rd+). B, Boxplot of age distribution across the three cancer groups. C, Bar plots show the distribution of NOUS-209 FSMs across the three cancer groups. D, Boxplots depict the distribution of NOUS-209 FSMs across the three cancer groups and by cancer type. E and F, Boxplots showing the distribution of NOUS-209 FSMs across stages in the colorectal cancer and muscle invasiveness in urothelial cancer cohorts, respectively. G, Boxplots showing the distribution of NOUS-209 FSMs in the colorectal cancer cohort stratified by the presence or absence of lymphovascular invasion. CRC, colorectal cancer; UC, urothelial cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Figure 2 from NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome
- Date Crossref
- 02/04/2026
- Éditeur
- American Association for Cancer Research (AACR)
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.